Roche Completes $1.9-Billion Acquisition of Flatiron Health

The acquisition is expected to accelerate progress towards personalized cancer healthcare.
Apr 09, 2018
By Pharmaceutical Technology Editors

Roche has completed its previously announced $1.9-billion acquisition of Flatiron Health, a privately held healthcare technology and services company headquartered in New York, NY, the pharma major announced on April 6, 2018. 

Under the agreement, Flatiron Health will continue to operate as a separate legal entity, and its current business model, network of partnerships, and overall objectives remain. The integrity of segregated patient-protected health information will be preserved, as will sales, marketing, provider-facing, and life science business activities.

Flatiron Health is a market leader in oncology-specific electronic health record (EHR) software as well as in the curation and development of real-world evidence for cancer research, Roche reports. Flatiron Health has created a technology platform designed to learn from the experience of every patient using a large network of community oncology practices and academic medical centers across the United States. The acquisition allows both companies to accelerate progress towards data-driven personalized healthcare in cancer.

Currently, Flatiron partners with more than 265 community cancer clinics, six major academic research centers, and 14 out of the top 15 therapeutic oncology companies.

Source: Roche

native1_300x100
lorem ipsum